Together, inhibiting NLRP3 inflammasome could bring down the “cytokine storm” and lung injury during SARS-CoV-2 infection, indicating NLRP3 inflammasome could be a target for COVID-19 treatment (see Table 1). Here, NLRP3 is linked to COVID-19.